Pacific Edge shares gain 6.5% on first commercial deal in Singapore

Pacific Edge shares gain 6.5% on first commercial deal in Singapore
Paul McBeth
By Paul McBeth Feb. 1 (BusinessDesk) - Pacific Edge shares rose 6.5 percent after the cancer diagnostics firm signed its first commercial deal to supply its suite of Cxbladder tests in Singapore.  The stock increased 2.5 cents to 41 cents after the Dunedin-based company said it reached a commercial agreement with a unit of Raffles Medical Group to use the bladder cancer tests in Singapore, the company said in a statement. Under the deal, the Raffles unit will coordinate specimen collection, shipping and reporting of Cxbladder tests for th...